IP Library Patent Application 17004857
Patent Application
App. No. 17/004,857

COMPOSITIONS AND METHODS FOR PRODUCING CLOSTRIDIAL COLLAGENASES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/004,857
Abstract

The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum. The method utilizes an improved medium for the cultivation of Clostridium histolyticum which includes a non-meat-derived (i.e., non-mammalian) peptone or vegetable peptone. The method includes one or more of: (1) reducing glucose content in the meat-free or vegetable-derived media; and (2) increasing the salt concentration in the meat-free or vegetable-derived media. Also provided is a drug product which includes collagenase I and collagenase II at an optimized fixed mass ratio, and which has a purity of greater than at least 95%.

Claims (18)

1 . A medium for the fermentation of Clostridium histolyticum comprising:

a. a peptone selected from the group consisting of Oxoid VG100 Vegetable Peptone made from pea, Oxoid VG200 Vegetable Peptone phosphate broth, BBL Phytone Peptone, and BD Difco Select Phytone;

b. yeast extract; and

c. less than about 5 g/L glucose;

wherein the pH of said medium is 7.5-7.9.

2 . The medium of claim 1 , containing greater than about 5 g/L salt.

3 . The medium of claim 2 , containing greater than about 7.5 g/L salt.

4 . The medium of claim 2 , wherein the salt is one or more of potassium phosphate, dipotassium phosphate, sodium phosphate, disodium phosphate, sodium chloride, potassium chloride, calcium chloride, or magnesium sulfate.

5 . The medium of claim 1 , further comprising one or more vitamins selected from the group consisting of ferrous sulfate, riboflavin, niacin, calcium pantothenate, pimelic acid, pyridoxine hydrochloride and thiamine hydrochloride.

6 . A medium for the fermentation of Clostridium histolyticum comprising:

a. a peptone selected from the group consisting of Oxoid VG100 Vegetable Peptone made from pea, Oxoid VG200 Vegetable Peptone phosphate broth, BBL Phytone Peptone, and BD Difco Select Phytone;

b. yeast extract; and

c. greater than about 5 g/L salt;

wherein the pH of said medium is 7.5-7.9.

7 . The medium of claim 6 , containing less than about 5 g/L glucose.

8 . The medium of claim 6 , containing greater than about 7.5 g/L salt.

9 . The medium of claim 6 , wherein the salt is one or more of potassium phosphate, dipotassium phosphate, sodium phosphate, disodium phosphate, sodium chloride, potassium chloride, calcium chloride, or magnesium sulfate.

10 . The medium of claim 6 , further comprising one or more vitamins selected from the group consisting of ferrous sulfate, riboflavin, niacin, calcium pantothenate, pimelic acid, pyridoxine hydrochloride and thiamine hydrochloride.

Assignments (9)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO BIOLOGICS LIMITED
Reel/Frame 067245/0693 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0737 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: BIOSPECIFICS TECHNOLOGIES LLC
To: ENDO USA, INC.
Reel/Frame 067198/0623 →
CHANGE OF NAME Recorded Jun 30, 2021
From: BIOSPECIFICS TECHNOLOGIES CORP.
To: BIOSPECIFICS TECHNOLOGIES LLC
Reel/Frame 056774/0545 →
SUPPLEMENT TO CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 14, 2020
From: BIOSPECIFICS TECHNOLOGIES CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 054751/0412 →
SUPPLEMENT TO CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Dec 2, 2020
From: BIOSPECIFICS TECHNOLOGIES CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 054575/0678 →